- Home
- NEGG vs ASMB Comparison
NEGG vs ASMB Comparison
Compare NEGG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ASMB
- Stock Information
- Founded
- NEGG 2001
- ASMB 2005
- Country
- NEGG United States
- ASMB United States
- Employees
- NEGG N/A
- ASMB N/A
- Industry
- NEGG Other Specialty Stores
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ASMB Health Care
- Exchange
- NEGG Nasdaq
- ASMB Nasdaq
- Market Cap
- NEGG 122.3M
- ASMB 141.8M
- IPO Year
- NEGG 2010
- ASMB 2010
- Fundamental
- Price
- NEGG $49.94
- ASMB $25.50
- Analyst Decision
- NEGG
- ASMB Strong Buy
- Analyst Count
- NEGG 0
- ASMB 4
- Target Price
- NEGG N/A
- ASMB $38.67
- AVG Volume (30 Days)
- NEGG 1.4M
- ASMB 147.2K
- Earning Date
- NEGG 08-29-2025
- ASMB 08-06-2025
- Dividend Yield
- NEGG N/A
- ASMB N/A
- EPS Growth
- NEGG N/A
- ASMB N/A
- EPS
- NEGG N/A
- ASMB N/A
- Revenue
- NEGG $1,313,127,000.00
- ASMB $33,247,000.00
- Revenue This Year
- NEGG N/A
- ASMB $12.44
- Revenue Next Year
- NEGG N/A
- ASMB N/A
- P/E Ratio
- NEGG N/A
- ASMB N/A
- Revenue Growth
- NEGG N/A
- ASMB 54.77
- 52 Week Low
- NEGG $3.32
- ASMB $7.75
- 52 Week High
- NEGG $137.84
- ASMB $27.17
- Technical
- Relative Strength Index (RSI)
- NEGG 44.81
- ASMB 65.04
- Support Level
- NEGG $86.27
- ASMB $24.98
- Resistance Level
- NEGG $137.84
- ASMB $27.17
- Average True Range (ATR)
- NEGG 19.91
- ASMB 1.13
- MACD
- NEGG -6.37
- ASMB -0.06
- Stochastic Oscillator
- NEGG 1.39
- ASMB 64.24
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.